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Abstract: The effects of chronic morphine treatment on P-endor- 
phin (PE)-immunoreactive (PE-ir) peptide levels were determined 
in the rat caudal medulla and different areas of the spinal cord. 
Seven days of morphine pelleting had no effect on total PE-ir pep- 
tides in the caudal medulla. In contrast, it significantly increased 
PE-ir peptide concentrations in the cervical and thoracic regions of 
the spinal cord compared with placebo-pelleted controls, whereas 
in the lumhosacral region this trend did not reach statistical signifi- 
cance. Injections o f  the opiate receptor antagonist naloxone 1 h 
before the rats were killed had no effect on the morphine-induced 
increases in the cord. Chromatographic analyses revealed that enzy- 
matic processing of PE-related peptides in the spinal cord seemed 
unaffected by the morphine and/or naloxone treatments. In light of 
previous data showing that morphine down-regulates BE biosynthe- 
sis in the hypothalamus, the present results suggest that the regula- 
tion of PE-ir peptides in the spinal cord is distinct from that found 
in other CNS areas. These data provide support for previous results 
suggesting that PE-expressing neurons may be intrinsic to the spinal 
cord. Key Words: Opiate-Endogenous opioid-Proopiomelano- 
cortin-Morphine-Nucleus tractus solitanus. Bronstein D. M. et 
al. Effects of chronic morphine treatment on @-endorphin-related 
peptides in the caudal medulla and spinal cord. J. Neurochem. 60, 
2304-2307 (1993). 
The endogenous opioid peptide ,&endorphin (PE) is 
found in numerous CNS regions and has been implicated in 
a wide variety of physiological and behavioral functions 
(Akil et al., 1984). PE is synthesized as part of the larger 
precursor protein, proopiomelanocortin (POMC). In addi- 
tion to the opioid-active 3 1-amino-acid peptide, BE,-,,, 
POMC produces several other BE-related peptides, includ- 
ing /3-lipotropin, BE,-,,, and and their acetylated de- 
rivatives, N-Ac-PE,..,, , N-Ac-PE,..,,, and N-Ac-PE,-,,. 
Different CNS regions contain unique mixes of BE-im- 
munoreactive (BE-ir) peptides. For example, whereas PE1-31 
accounts for 50-75'% of the total PE-ir activity in most ros- 
tral brain structures, it represents only 25% of the total PE-ir 
activity in the nucleus tractus solitarius (NTS) (Dores et al., 
1986) and as little as 10% in the sacral portions of the spinal 
cord (Gianoulakis ;and Angelogianni, 1989). The regional 
differences in POMC peptide products are due, in part, to 
their originating from separate POMC cell groups. BE-ir ac- 
tivity found in forebrain and midbrain areas is derived al- 
most exclusively from perikarya in the arcuate nucleus of 
the hypothalamus (Watson et al., 1977; Bloom et al., 1978; 
Krieger et al., 1980). In more caudal areas ofthe CNS, BE-ir 
activity originates primarily from a small number of cells 
scattered around the NTS (Schwartzberg and Nakane, 
1983; Khachaturiari et al., 1985; Palkovits and Eskay, 1987; 
Palkovits et al., 1987). 
PE-ir activity has been detected in nerve fibers in the spi- 
nal cord (Khachaturian et al., 1985; Tsou et al., 1986), but it 
has generally been assumed that these fibers derived from 
supraspinal sources as POMC-immunoreactive cell bodies 
have never been observed in the cord itself. Recently, how- 
ever, several lines of evidence raise the possibility that PE-ir 
peptides might be expressed in cells intrinsic to the spinal 
cord: (a) The pattern of POMC processing in the spinal 
cord, i.e., higher-molecular-weight species make up a rela- 
tively large percentage of the total BE-ir activity, is distinct 
from that found in the arcuate or NTS POMC systems. (b) 
Our laboratory demonstrated that BE-ir activity persisted in 
lower spinal cord levels even after complete transections at 
higher spinal levels (Gutstein et al., 1992). (c) POMC 
mRNA has recently been detected in the spinal cord (Plan- 
tinga et al., 1992). 1; in fact, spinal cord POMC cells exist, it 
is reasonable to believe that they might be regulated differ- 
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ently from the arcuate and/or NTS POMC systems. This 
was recently found to be the case, as PE biosynthesis ap- 
peared to be up-regulated by chronic naltrexone treatment 
in arcuate POMC neurons, whereas PE-ir peptide levels in 
the NTS and spinal cord remained unchanged (Bronstein et 
al., 1993). 
In light of previous reports that chronic morphine down- 
regulates POMC peptide biosynthesis in the rostral arcuate 
system (Mocchetti et al., 1989; Bronstein et al., 1990), the 
present study was undertaken to assess the effects of chronic 
morphine administration on PE-ir peptides in the caudal 
medulla and spinal cord. 
MATERIALS AND METHODS 
Male Sprague-Dawley rats were implanted with mor- 
phine (75 mg per pellet) or placebo pellets over a 7-day 
period (one pellet on the first day and three more on the 
fourth day) and then received an intraperitoneal injection of 
saline or naloxone ( 1  mg/kg) 1 h before they were killed 
(Bronstein et al., 1990). The four treatment groups were 
designated as placebo/saline (PS), morphine/saline (MS), 
placebo/naloxone (PN), and morphine/naloxone (MN). 
The caudal medulla, including the NTS (hereafter desig- 
nated as NTS), and different spinal cord regions [cervical, 
thoracic, and lumbosacral (CSC, TSC, and SSC, respec- 
tively)] were collected on ice and frozen at -80°C until 
assayed for PE-ir activity. Mean f SE tissue weights (mg) for 
the NTS, CSC, TSC, and SSC were 80 L 2,147 f 6,193 k 9, 
and 142 f 7, respectively. Peptides were extracted and 
quantified by radioimmunoassay (RIA) as described previ- 
ously (Akil et al., 1979). Because the antibody used recog- 
nized any peptide containing the midportion sequence of 
(amino acids 17-27), RIAs of crude brain or spinal 
cord extracts provided a measure of total BE-ir activity. 
Concentrations of different molecular-weight PE-ir peptides 
in the NTS, CSC, and TSC were determined by chromato- 
graphic separation on Sephadex (3-50 columns followed by 
RIA of the collected fractions (Bronstein et al., 1990). Re- 
sults were analyzed by two-way ANOVA, with pelleting 
(placebo or morphine) and injection (saline or naloxone) as 
the two independent variables. 
RESULTS 
The data presented here were collected from two indepen- 
dent experiments that gave qualitatively identical effects. 
Seven days of morphine pelleting had no effect on total 
PE-ir peptide concentrations in the NTS (Fig. 1). In con- 
trast, it significantly increased PE-ir peptide concentrations 
in the CSC and TSC ( F  = 4.19, p < 0.05; and F = 5.06, p 
< 0.05, respectively). In both regions, total BE-ir peptide 
concentrations were roughly 50% higher in morphine- than 
in placebo-treated animals. Morphine tended to elevate PE- 
ir activity in the SSC as well, but this increase (-30%) did 
not reach statistical significance (F  = 1.59, p = 0.2 1). Injec- 
tions of naloxone to placebo-treated animals did not alter 
total BE-ir peptide levels in any region, nor did it affect the 
morphine-induced increases in PE-ir activity in the spinal 
cord. 
Different-sized PE-related peptides that contributed to 
the total BE-ir activity found in crude extracts were sepa- 
rated by gel filtration chromatography and then quantified 
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FIG. 1. Effect of chronic morphine treatment on PE-ir peptide 
concentrations in the caudal medulla (NTS) and spinal cord (CSC, 
TSC, and SSC). Rats were implanted subcutaneously with mor- 
phine (75 mg) or placebo pellets over a 7-day period. One hour 
before the animals were killed, they received injections of nalox- 
one (1 mg/kg) or saline vehicle. Caudal medulla and spinal cord 
regions were assayed for total PE-ir peptide by RIA. Data were 
collected from two independent experiments and expressed as 
percentages of the PS mean value from each experiment. Abso- 
lute concentrations of PE-ir peptide in the NTS, CSC, TSC, and 
SSC for PS-treated animals were 7.0 & 0.9, 6.9 rt 2.1, 2.1 f 0.3, 
and 0.66 f 0.11 fmol/mg of tissue, respectively. As naloxone 
treatment had no effect in any region, the vehicle and naloxone 
groups have been pooled, i.e., PS + PN = placebo and MS + MN 
= morphine, to illustrate more clearly morphine versus placebo 
differences. Data are mean r+_ SEM (bars) values of 16-27 ani- 
mals. 
by RIA. Three major peaks of PE-ir activity were detected. 
The molecular masses of these peaks corresponded to 0-S- 
potropin (1 1 kDa), PE,-,, (3.5 kDa), and PE,-,,/PE,-,, (3.0 
kDa). In agreement with previous data (Dores et al., 1986; 
Gianoulakis and Angelogianni, 1989; Gutstein et al., 1992), 
the relative heights of the three peaks varied in the regions 
analyzed (Fig. 2). There was progressively less processing of 
POMC precursor to PE-related peptides as one descended 
from the NTS to the TSC, i.e., more caudal spinal cord 
regions contained higher proportions of larger-molecular- 
weight PE-ir species compared with the NTS or CSC. This 
pattern of POMC processing is in contrast to that seen in the 
hypothalamus, where virtually all POMC is processed to 
fiE,-,,- and ~E,-,,/PE,-,,-size material. Chronic morphine 
treatment, with or without naloxone, had no appreciable 
effect on the chromatographic profiles in any of the regions 
examined. 
DISCUSSION 
The results of this study demonstrate that chronic mor- 
phine treatment increases PE-ir peptide concentrations in 
the spinal cord but not the caudal medulla. To our knowl- 
edge, this is the first demonstration that BE-ir peptides in the 
spinal cord can be pharmacologically regulated. These re- 
sults may prove significant in two respects. First, the finding 
that 7 days of morphine pelleting increases PE-ir activity in 
the spinal cord but not in the NTS or in other more rostral 
brain regions (Bronstein et al., 1990; Berglund et al., 1989; 
Mocchetti et al., 1989) indicates that spinal PE-ir activity 
may be uniquely regulated by opiates. This would support 
previous data (Gutstein et al., 1992; Platinga et al., 1992) 
suggesting the existence of POMC cells intrinsic to the spi- 
nal cord. Second, the present data demonstrate that PE-ir 
peptide levels in the spinal cord are influenced by opiate 
J .  Neurochem., Vol. 60. No. 6, I993 
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FIG. 2. Representative chromato- 
graphic profiles of PE-ir peptide in the 
NTS and spinal cord of control (PS) ani- 
mals. Animals were treated and tissue 
was collected as described in Fig. 1. 
Crude extracts from two to four ani- 
mals were pooled and chromato- 
graphed on a Sephadex G-50 column 
developed with 1 YO formic acid contain- 
ing 0.1% bovine serum albumin. Col- 
lected fractions were assayed for BE-ir 
activity. Data are expressed as percent- 
ages of the total PE-ir activity detected 
(total PE-ir content was determined by 
summating BE-ir peptide levels from 
each of the individual fractions). 
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receptor activation. This is consistent with a possible role 
for BE-ir peptides in various opioid-mediated functions in 
the spinal cord, e.g., analgesia. Previously, chronic naltrex- 
one treatment was shown not to alter BE-ir peptide concen- 
trations in the spinal cord (Bronstein et at., 1993), suggest- 
ing that spinal cord BE-ir activity was not under tonic inhibi- 
tory control by endogenous opioids. Thus, if@E-ir activity is 
to have a physiological role in opiate-mediated processes in 
the spinal cord, it may first require the activation of endoge- 
nous opioid-containing neurons. 
It is presently not known whether the effects of morphine 
on spinal cord PE-ir peptides were direct, i.e., on putative 
POMC cells in the spinal cord, or indirect, i.e., mediated by 
supraspinal or intraspinal neurons. It is also not clear 
whether the increase in total PE-ir activity represents an 
induction of (3E biosynthesis subsequent to increased neuro- 
nal activation or an inhibition of release and accumulation 
of peptide subsequent to decreased neural activity. In other 
POMC cells, such as those in the pituitary gland or arcuate 
nucleus, additional parameters of POMC biosynthesis, e.g., 
POMC mRNA levels, rates of POMC translation or process- 
ing, and PE release, provide information that helps distin- 
guish whether biosynthesis has been stimulated or re- 
pressed. In the case of the spinal cord, however, these mea- 
sures are currently technically infeasible or extremely 
difficult owing to the fact that expression levels are low (see 
Platinga et al., 1992). We were able to analyze different 
molecular-weight PE-ir forms and found that morphine, 
alone or in combination with naloxone, did not appear to 
alter the relative amounts of different BE-ir peptides in the 
NTS or spinal cord. This differs from the situation in the 
hypothalamus where 3 days of morphine treatment in- 
creased total BE-ir activity primarily because of a selective 
increase in PE,-27/PE1-26 concentrations (Bronstein et al., 
1990) and where an 8-day treatment with naltrexone de- 
creased total BE-ir activity in large part because of a decrease 
in PE,-,,/PE,-,, levels (Bronstein et al., 1993). 
The present results, together with those from previous 
studies (Mocchetti et al., 1989; Bronstein et al., 1990, 1993), 
suggest that hypothalamic, NTS, and spinal cord BE species 
are differentially regulated by chronic opiate agonist or an- 
tagonist treatment. The rostra1 POMC system, with somata 
localized in and around the arcuate nucleus, appears to be 
down-regulated by opiate agonists and up-regulated by 
opiate antagonists, suggesting a tonic inhibitory control of 
these cells by one or more of the endogenous opioid pep- 
csc 
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tides. POMC neurons in the NTS appear unaffected by ei- 
ther opiate agonist or antagonist treatment. Finally, spinal 
cord PE-ir activity is elevated by chronic morphine treat- 
ment but unaffected by chronic naltrexone treatment. The 
differential regulation of PE synthesis by opiate receptor 
ligands provides support for the hypothesis that there may 
be an intrinsic P O h K  system in the spinal cord in addition 
to those originating in the arcuate nucleus and NTS. This 
could have important implications for a possible role of 
PE-ir peptides in antinociceptive and/or autonomic func- 
tions at the spinal level. 
Acknowledgment: This work was supported in part by a 
Medical Research Council of Canada Postdoctoral Fellow- 
ship (D.M.B.), a University of Michigan Department of An- 
esthesiology Starter Grant (H.B.G.), and NIDA grant 
DA02265 (H.A.). Morphine and placebo pellets were pro- 
vided by the National Institute of Drug Abuse. 
REFERENCES 
Akil H., Watson S. J., Barchas J. D., and Li C. H. (1 979) Beta-en- 
dorphin immunoreactivity in rat and human blood radioim- 
munoassay, comparative levels, and physiological alterations. 
Life Sci. 24, 1659-1666. 
Akil H., Watson S. J.. Young E., Lewis M. E., Khachaturian H., 
and Walker J. M. (1984) Endogenous opioids: biology and 
function. Annu. Rev. Neurosci. 7, 223-255. 
Berglund L. A., Millington W. R., and Simpkins J. W. (1989) Go- 
nadal steroid and chronic morphine treatment do not change 
the posttranslational processing of 0-endorphin in the rat 
brain. Lifr Sci. 44, 591-601. 
Bloom F., Battenberg E., Rossier J., Ling N., and Guillemin R. 
(1978) Neurons containing beta-endorphin in rat brain exist 
separately from those containing enkephalin: immunocyto- 
chemical studies. Proc. Natl. Acad. Sci. USA 75, I59 1- 1595. 
Bronstein D. M., Przewlocki R., and Akil H. (1990) Effects of mor- 
phine treatment on pro-opiomelanocortin systems in rat brain. 
Brain Rex 519, 102-1 111 
Bronstein D. M.. Dav !Y. C.. Gutstein H. B.. Truiillo K. A., and Akil 
H. (1993) Pre- akl posttranslational regulation of P-endorphin 
biosynthesis in the CNS: effects of chronic naltrexone treat- 
ment. J.  Neurochem. 60,40-49. 
Dores R. M., Jain M.. and Akil H. (1986) Characterization of the 
forms of @-endorphin and a-MSH in the caudal medulla of the 
rat and guinea pig. Brain Res. 317, 25 1-260. 
J.  Neurochem., Vol. 60, No. 6, 1993 
CHRONIC MORPHINE AND p- ENDOR PHIN-R ELA TED PEPTIDES 2307 
Gianoulakis C. and Angelogianni P. (1989) Characterization of 0- 
endorphin peptides in the spinal cord of the rat. Peptides 10, 
1049-1054. 
Gutstein H. B., Bronstein D. M., and Akil H. ( 1  992) 0-Endorphin 
processing and cellular origins in rat spinal cord. Pain 51,241- 
247. 
Khachaturian H., Lewis M. E., Tsou K., and Watson S. J.  (1985) 
0-Endorphin, a-MSH, ACTH, and related peptides, in Hand- 
book ofChemica1 Neuroanatomy, Vol. 4: GABA and Neuropep- 
tides in the CNS, Part Z(Bjorklund A. and Hokfelt T., eds), pp. 
2 16-272. Elsevier, Amsterdam. 
Krieger D. T., Liotta A. S., Brownstein M. J., and Zimmerman 
E. A. (1980) ACTH, P-lipotropin, and related peptides in 
brain, pituitary, and blood. Recent Prog. Horm. Res. 36,277- 
344. 
Mocchetti I., Ritter A,, and Costa E. (1989) Down-regulation of 
pro-opiomelanocortin synthesis and beta-endorphin utiliza- 
tion in hypothalamus of morphine-tolerant rats. J.  Mol. Neuro- 
sci. I ,  33-38. 
Palkovits M. and Eskay R. L. (1987) Distribution and possible ori- 
gin of 0-endorphin and ACTH in discrete brainstem nuclei of 
rats. Neuropeptides 9, 123-137. 
Palkovits M., Mezey E., and Eskay R. L. (1987) Pro-opiomelano- 
cortin-derived peptides (ACTHIP-endorphinla-MSH) in 
brainstem baroreceptor areas of the rat. Brain Res. 436, 323- 
328. 
Plantinga L. C., Verhaagen J., Edwards P. M., Schrama L. H., Bur- 
bach J. P. H., and Gispen W. H. (1992) Expression of the 
pro-opiomelanocortin gene in dorsal root ganglia, spinal cord 
and sciatic nerve after sciatic nerve crush in the rat. Mol. Brain 
Res. 16, 135-142. 
Schwartzberg D. G. and Nakane P. K. (1983) ACTH-related pep- 
tide containing neurons within the medulla oblongata of the 
rat. Bruin Res. 276, 351-356. 
Tsou K., Khachaturian H., Akil H., and Watson S .  J. (1986) Immu- 
nocytochemical localization of pro-opiomelanocortin-derived 
peptides in the adult rat spinal cord. Brain Res. 378, 28-35. 
Watson S. J., Barchas J.  D., and Li C. H. (1977) Beta-lipotropin: 
localization in cells and axons in rat brain by immunocyto- 
chemistry. Proc. Natl. Acad. Sci. USA 74, 5 155-5 158. 
J.  Neurochem., Vol. 60, No. 6. 1993 
